Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Vaxcyte (NASDAQ:PCVX) released its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28, Briefing.com reports.

Vaxcyte Stock Down 1.8 %

Vaxcyte stock opened at $65.57 on Friday. The company’s 50 day moving average is $66.14 and its two-hundred day moving average is $62.45. The firm has a market cap of $7.11 billion, a PE ratio of -15.88 and a beta of 0.94. Vaxcyte has a 52-week low of $44.20 and a 52-week high of $82.04.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the completion of the transaction, the chief executive officer now directly owns 477,847 shares in the company, valued at $31,982,299.71. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, SVP Elvia Cowan sold 11,678 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $74.08, for a total value of $865,106.24. Following the transaction, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00. Following the completion of the transaction, the chief executive officer now owns 477,847 shares in the company, valued at $31,982,299.71. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,294 shares of company stock valued at $4,254,105. 3.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PCVX has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a research report on Thursday.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.